secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2023-10-24T23:59:59+00:00
Accession:  0001013762-23-006005
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma to spin off Citius Oncology via merger with SPAC TenX Keane
-------------------------------------------------------------------------

- Citius Pharma (CTXR) entered a merger agreement for its subsidiary Citius Oncology to combine with TenX Keane Acquisition.
- Upon close, TenX will domesticate to Delaware and change name to 'Citius Oncology, Inc.'; expected close first half 2024.
- SpinCo shares convert to New Citius Oncology shares using Base Exchange Ratio of 67.5M / outstanding SpinCo shares.
- Termination rights include FDA CRL for Lymphir; $5M termination fee payable by Citius Pharma under certain conditions.
- Sponsor 10XYZ Holdings supports transaction; post-close registration rights and shared services agreements planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/0001013762-23-006005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/ea186984-8k425_citius.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-006005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer